Saturday 17 October 2026
Export HLN’s income statement to Excel — free account
Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
10.13
0.19
+1.91%
Follow HLN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
8 | 8 | — | — | — | — | — |
P/E ratio |
22.54 | 21.27 | 20.41 | 20.41 | 20.41 | 20.41 | 20.41 |
Altman Z-Score |
3.04 | 2.78 | 2.72 | 2.53 | — | — | — |
P/S ratio |
2.57 | 2.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.27 | 3.95 | 4.07 | 3.74 | — | 7.98 | 4.86 |
P/FCF ratio |
9.02 | 9.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.60) | (2.52) | (2.61) | — | — | (2.59) | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend Safety Score |
66 | — | — | — | — | — | — |
P/B ratio |
2.18 | 2.08 | 1.83 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.14 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
13.39 | 12.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
9.61 | 10.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF |
11.04 | 11.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
0.70 | 0.76 | 0.64 | 0.61 | 1.01 | 0.99 | 1.02 |
Current Ratio |
0.92 | 0.98 | 1.04 | 0.93 | 1.24 | 1.25 | 1.36 |
Net Debt/EBITDA |
2.63 | 3.11 | 3.65 | 4.62 | 0.26 | 0.07 | 0.15 |
Debt/Assets |
26.38% | 29.51% | 27.77% | 29.99% | 0.00% | 1.43% | 1.80% |
Debt/Equity |
0.52 | 0.62 | 0.57 | 0.63 | 0.04 | 0.02 | 0.02 |
Asset Turnover |
0.33 | 0.33 | 0.33 | 0.30 | 0.55 | 0.29 | 0.00 |
Operating CF/Net income |
1.58 | 1.60 | 2.00 | 1.95 | 0.98 | 1.23 | 1.19 |
Capex/Depreciation |
(1.15) | 0.02 | (0.29) | (1.02) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
7.09 | 5.74 | 4.97 | 7.07 | 300.46 | 106.53 | 82.43 |
| 10.35% | 8.87% | 6.34% | 4.69% | 5.26% | 4.37% | 0.00% | |
| 5.06% | 4.27% | 3.06% | 2.92% | 8.04% | 3.35% | 0.00% | |
ROIC |
6.34% | 5.72% | 4.96% | 4.35% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
112.03% | 84.08% | 53.58% | 73.31% | 51.96% | 44.11% | 20.71% |
Average Days of Receivables |
70.25 | 69.80 | 62.88 | 66.46 | 148.41 | 134.72 | 173.16 |
Research and Development Expense of Revenue |
2.86% | 2.65% | 2.75% | 2.76% | 2.69% | 3.07% | 3.44% |
Selling, General and Administrative Expense of Revenue |
39.56% | 39.63% | 39.05% | 41.29% | 39.18% | 38.36% | 32.77% |
Intangible Assets out of Total Assets |
0.79 | 0.76 | 0.79 | 0.82 | 0.00 | 0.80 | 0.78 |
Share Based Compensation of Revenue |
0.78% | 0.91% | 0.67% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.34) | (0.34) | (0.44) | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.44% | 4.70% | 4.90% | 4.90% | 4.90% | 4.90% | 4.90% |
Free Cash Flow Yield |
11.09% | 10.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
3.24 | 3.14 | 3.05 | 2.91 | 2.79 | 2.93 | 2.41 |
Operating CF per Share |
0.77 | 0.64 | 0.57 | 0.55 | 0.40 | 0.42 | 0.22 |
Capex per Share |
(0.12) | 0.00 | (0.02) | (0.08) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.65 | 0.65 | 0.54 | 0.47 | 0.40 | 0.42 | 0.22 |
Cash per Share |
0.39 | 0.63 | 0.28 | 0.18 | 0.12 | 0.10 | 0.10 |
Shareholders Equity per Share |
4.84 | 4.54 | 4.51 | 4.41 | 7.71 | 7.74 | 7.78 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.84 | 4.54 | 4.51 | 4.41 | 7.71 | 7.74 | 7.78 |
Free Cash Flow |
2,928.83 | 2,949.39 | 2,500.24 | 2,190.55 | 1,833.78 | 1,927.40 | 1,027.63 |
Working Capital |
(505.06) | (120.12) | 221.41 | (384.68) | 1,368.92 | 1,361.64 | 2,028.95 |
Capital Expenditures |
(544.62) | 8.95 | (111.95) | (361.17) | (402.70) | (435.62) | (319.74) |
Net Current Asset Value |
(15,291.64) | (15,811.46) | (15,558.70) | (17,686.43) | (3,675.68) | (3,971.23) | (3,273.68) |
EV/EBIT |
17.53 | 16.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.00 | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
14.32 | 13.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.19 | 0.18 | 0.17 | 0.16 | 0.16 | 0.19 | 0.16 |
Cash ROIC |
8.41% | 8.07% | 7.38% | 6.42% | 4.89% | 5.22% | 2.76% |
Accounts Receivable Turnover |
5.25 | 5.56 | 5.78 | 3.49 | 2.52 | 2.63 | 0.00 |
Accounts Payable Turnover |
1.08 | 1.24 | 1.28 | 1.67 | 2.64 | 3.19 | 0.00 |
Inventory Turnover |
3.63 | 3.44 | 3.31 | 3.59 | 3.76 | 3.77 | 0.00 |
Average Days of Payables |
344.67 | 306.72 | 282.54 | 308.73 | 138.99 | 122.83 | 119.19 |
Days of Inventory on Hand |
94.72 | 98.51 | 112.83 | 114.93 | 96.55 | 86.99 | 120.18 |
Average Receivables |
2,772.26 | 2,583.40 | 2,433.61 | 3,844.97 | 5,122.98 | 5,147.40 | — |
Average Payables |
4,826.69 | 4,560.31 | 4,432.40 | 3,164.41 | 1,842.81 | 1,707.94 | — |
Average Inventory |
1,436.18 | 1,636.06 | 1,709.38 | 1,476.24 | 1,292.57 | 1,446.71 | — |
Average Assets |
43,440.16 | 43,106.08 | 42,711.85 | 44,908.05 | 23,376.71 | 46,870.79 | — |
Average Common Equity |
21,235.05 | 20,770.93 | 20,582.43 | 27,985.26 | 35,692.36 | 35,859.27 | — |
Columns are period end dates